Virginia narrow therapeutics bill refers decision on substitutions to state pharmacy board.
Executive Summary
NARROW THERAPEUTICS INDEX DECISION TO BE REFERRED TO VIRGINIA PHARMACY BOARD, under legislation passed 35-4 with one abstention by the Virginia Senate Feb. 20. HB 2736 was introduced by Jay DeBoer (D), who represents Virginia's 63rd district, where Merck facilities are located. DuPont Merck has been a prominent supporter of measures restricting substitution of generics for brand name products, since its anticoagulant product Coumadin (warfarin) is facing generic competition in the near future.